Mechthild Krause

Mechthild Krause

Auto-generated profile, based on publicly available information

Mechthild Krause

National Center for Tumor Diseases Dresden (NCT/UCC), Faculty of Medicine, TU Dresden, Dresden, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2016 in Nature Reviews Cancer
Verified
Journal Article
Closed access
MBMichael Baumann
Michael Baumann
MKMechthild Krause
Mechthild Krause
JOJens Overgaard
Jens Overgaard
JDJürgen Debus
Jürgen Debus
SBSoren Bentzen
Soren Bentzen
TBThomas Bortfeld
Thomas Bortfeld

30 May 2008 in Nature Reviews Cancer
Verified
Journal Article
Closed access
MBMichael Baumann
Michael Baumann
MKMechthild Krause
Mechthild Krause
RHRichard Hill
Richard Hill

1 January 2015 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
BOBirgitte V. Offersen
Birgitte V. Offersen
LBLiesbeth J. Boersma
Liesbeth J. Boersma
CKCarine Kirkove
Carine Kirkove
SHSandra Hol
Sandra Hol
MAMarianne C. Aznar
Marianne C. Aznar
PPPhilip Poortmans
Philip Poortmans

27 April 2018 in Gut
Verified
Journal Article
Open access
PDF file
TSTherese Seidlitz
Therese Seidlitz
SMSebastian R Merker
Sebastian R Merker
ARAlexander Rothe
Alexander Rothe
FZFalk Zakrzewski
Falk Zakrzewski
CNCläre Von Neubeck
Cläre Von Neubeck
DSDaniel E Stange
Daniel E Stange
Objective: Gastric cancer is the second leading cause of cancer-related deaths and the fifth most common malignancy worldwide. In this study, human and mouse gastric cancer organoids were generated to model the disease and perform drug testing to delineate treatment strategies.Design: Human gastric cancer organoid cultures were established, samples classified according to their molecular profile and their response to conventional chemotherapeutics tested. Targeted treatment was performed according to specific druggable mutations. Mouse gastric cancer organoid cultures were generated carrying molecular subtype-specific alterations.Results: Twenty human gastric cancer organoid cultures were established and four selected for a comprehensive in-depth analysis. Organoids demonstrated divergent growth characteristics and morphologies. Immunohistochemistry showed similar characteristics to the corresponding primary tissue. A divergent response to 5-fluoruracil, oxaliplatin, irinotecan, epirubicin and docetaxel treatment was observed. Whole genome sequencing revealed a mutational spectrum that corresponded to the previously identified microsatellite instable, genomic stable and chromosomal instable subtypes of gastric cancer. The mutational landscape allowed targeted therapy with trastuzumab for ERBB2 alterations and palbociclib for CDKN2A loss. Mouse cancer organoids carrying Kras and Tp53 or Apc and Cdh1 mutations were characterised and serve as model system to study the signalling of induced pathways.Conclusion: We generated human and mouse gastric cancer organoids modelling typical characteristics and altered pathways of human gastric cancer. Successful interference with activated pathways demonstrates their potential usefulness as living biomarkers for therapy response testing.

1 January 2017 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
MKMechthild Krause
Mechthild Krause
Anna DubrovskaAnna Dubrovska
Anna Dubrovska
ALAnnett Linge
Annett Linge
MBMichael Baumann
Michael Baumann
Inactivation of cancer stem cells (CSCs) is of utmost importance for tumor cure after radiotherapy. An increasing body of evidence complies with a higher radioresistance of CSCs compared to the mass of tumor cells, supporting the use of CSC related biomarkers for prediction of radiotherapy outcome. Treatment individualization strategies for patient groups with vastly different risk of recurrence will most likely require application of more than one biomarker. Specifically, inclusion of established biomarkers like tumor size for primary radio(chemo)therapy or human papilloma virus (HPV) infection status in head and neck squamous cell carcinoma seems to be of very high relevance. The high heterogeneity of CSC subclones along with changes of the functional behavior of individual tumors under treatment underlines the importance of the selection of the optimal timepoint(s) of biomarker evaluation, but also provides a potential therapeutic target for combined treatment approaches with irradiation.

1 January 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
BOBirgitte V. Offersen
Birgitte V. Offersen
LBLiesbeth J. Boersma
Liesbeth J. Boersma
CKCarine Kirkove
Carine Kirkove
SHSandra Hol
Sandra Hol
MAMarianne C. Aznar
Marianne C. Aznar
PPPhilip Poortmans
Philip Poortmans